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ABSTRACT   
Aim:  In 2004 wide variation in the investigation and management of gastro-oesophageal 
reflux (GOR) of infants on UK major neonatal units was demonstrated.  Our aim was to re-
survey neonatal practitioners to determine current practice and whether it was now evidence 
based.   
Methods:  A questionnaire was sent to all 207 UK neonatal units.  
Results:  Responses were obtained from 84% of units. The most frequent “investigation” 
was a trial of therapy (83% of units); pH studies were used in 38%, upper GI contrast studies 
in 19% and multichannel intraluminal impedance (MII)/pH studies in 5%. Only six units 
suggested a threshold for an abnormal pH study and two units for an abnormal MII study.  
Infants were commenced on anti-reflux medication without investigation always in 32% of 
units, often in 29%, occasionally in 19% and only never in 1%. Gaviscon was used as first 
line treatment in 60% of units, other medications included ranitidine in 53%, thickening 
agents in 27%, proton pump inhibitors in 23%, domperidone in 22% and erythromycin in 6%.       
Conclusion: There remains a wide variation in diagnostic and treatment strategies for 
infants with suspected GOR on neonatal intensive care units, emphasizing the need for 
randomised trials to determine appropriate GOR management.  
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• Many infants on neonatal units receive treatment for suspected gastro-oesophageal 
reflux (GOR).  
• We have demonstrated a wide variation in the investigation and management 
strategies of suspected GOR on neonatal units. 
• There is a need for randomised trials to identify appropriate diagnostic and 




Gastro-oesophageal reflux (GOR), the retrograde movement of gastric contents into the 
oesophagus, is a common event even in healthy infants (1). Gastro-oesophageal reflux 
disease (GORD) occurs when the reflux causes troublesome symptoms.  The symptoms 
attributed to GORD, however, are varied and non-specific and include that the infant is 
unsettled, has poor weight gain, back arching, poor feeding and/or respiratory disturbance, 
including apnoea. Many infants on neonatal intensive care units (NICUs) are treated for 
GORD, for example approximately 25% of 1598 extremely low birth weight (<1000g) infants 
were discharged from NICUs in the USA on anti-reflux medication (2).  In 2004, a survey 
was reported of the diagnostic and treatment strategies for GORD in major NICUs in the 
United Kingdom (3).  A wide variation in strategies was demonstrated, which the authors 
postulated resulted from the lack of published evidence (3).  The aim of this study was to 
conduct a further survey more than a decade later to determine current diagnostic and 




A questionnaire was sent to clinicians of all 207 UK neonatal units identified from the 
National Neonatal Audit Programme, the British Association of Perinatal Medicine directory 
and a departmental database established for previous audits.  Practitioners were asked 
which investigations were used, what thresholds were considered abnormal for pH and 
multichannel intraluminal impendence (MII) studies and what proportion of infants were 
investigated prior to initiation of therapy for GORD.  In addition, they were asked which 
medications were used and what criteria were used for discontinuing treatment. The survey 





Responses were obtained from 84% of the 207 UK neonatal units. To establish the 
diagnosis, the majority (58%) of units used a trial of treatment; investigations were used less 
frequently (Table 1) Only six units suggested a threshold for an abnormal pH study. An acid 
index of more than 5% was considered abnormal in one unit, more than 7% in two units and 
more than 10% in three units. Only two units gave a threshold for an abnormal MII study and 
in both this was more than 50 reflux events in 24 hours. In only two units (1%) was anti-
reflux medication never started prior to investigation and in 32% of units medication was 
always started without investigation. In a further 29% of units treatment was often started 
without investigation and in another 19% of units occasionally without investigation.   
 
The type of treatment used varied widely between neonatal units (Table 2).  Therapy was 
discontinued in 44% units when symptoms resolved, in 9% of units prior to discharge and in 
19% of units at the first out-patient appointment. Three percent of units undertook a trial of 
withdrawing treatment and medication was discontinued if there was no clear benefit.  
 
DISCUSSION 
We had demonstrated that there was a wide variation in the current investigation and 
management strategies for infants with suspected GORD being cared for on UK neonatal 
units.   The previous survey (3) also showed a similar wide variation, but was only of 
prematurely born infants cared for in level two and three neonatal units.  In our survey, all 
207 neonatal units of all levels were surveyed with an 84% response rate.  In addition, we 




A trial of therapy was the most commonly used approach to diagnose GORD and few 
neonatal units had access to pH or MII studies. Yet, although the latest guidelines from 
ESPGHAN conclude there is little evidence for any investigation of GORD in infants 
including neonates, they state that if there is a strong suspicion that reflux is contributing to 
apnoea combined pH/MII and polysomnography would be helpful.  Indeed, addition of MII 
monitoring to conventional pH monitoring improved the diagnostic yield in 16 symptomatic 
preterm infants and seven neonates with apnoea (4).  In contrast, in 54 infants with ages 
from 1-330 days, the prevalence of GOR as detected by MII-pH was low (10%), despite the 
infants having a strong clinical suspicion for reflux (5).  In addition, in another study the 
majority of suspected clinical reflux behaviours did not correlate with reflux events (6). 
   
In the 2004 survey, 30% of units used pH monitoring on a regular basis (3). The current 
survey revealed that still only a minority of units (34%) were using pH monitoring, perhaps 
reflecting the poor correlation between symptoms and the results of investigations (7) and/or 
the problems with interpreting the results.  Reflex events are diagnosed if there is a 
reduction in the oesophageal pH below four.  In infants, it has been suggested that such 
criteria may be of limited use as the gastric contents can be buffered by milk (8). The 
concerns regarding the buffering effect of milk, however, were based on data from studies 
with small numbers of heterogeneous groups of patients (9, 10). Other studies have shown 
that gastric pH dispersion is not homogeneous and have failed to find a significant effect of 
gastric buffering on the reflux index (11, 12).   
 
In one study, although no statistically significant correlation was found between the pH reflux 
index and the duration of treatment, a significant correlation was demonstrated between MII 
results and the duration of treatment, but the correlation was weak (r2=0.36) (13).  In another 
study, amongst 64 infants with GOR symptoms who underwent MII/pH monitoring in the first 
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weeks after birth and then sequentially over the next three years, impedance bolus exposure 
index and proximal reflux frequency were most predictive of the duration of symptoms (5). 
Yet, we found only 5% of units used this technique. Only two units gave a threshold for an 
abnormal MII study, both used more than 50 events in 24 hours, whereas the recommended 
standard is 100 events in 24 hours. Upper GI contrast studies were used in 23% of units to 
diagnose GORD and, although they have a role in investigating anatomical abnormalities, 
they cannot quantify the frequency of reflux events and hence determine the severity (14, 
15).  
 
We have demonstrated that there remains a wide variety of medications used for GORD.  
Gaviscon was the most commonly used treatment, perhaps reflecting it has minimal side-
effects (16). Gaviscon, however, is contraindicated in those with known or suspected 
impairment of renal function and should not be given with other preparations that contain 
thickening agents. Gaviscon is an alginate-based formulation and acts as a physical 
protection of the gastric mucosa.  In the presence of gastric acid, sodium alginate 
precipitates to form a low-density but viscous gel.  The sodium bicarbonate, usually 
contained in such formulations, is converted to carbon dioxide and is entrapped within the 
gel, forming a foam which floats on the surface of gastric content, preferentially moving into 
the esophagus instead of acidic gastric contents during GOR episodes. Gaviscon®, however 
did not reduce the frequency of GOR related apnoeas in 28 preterm infants studied with a 
six hour recording of combined MII and pH monitoring and polysomnography (17).   
 
Other medications included histamine two receptor blockers, such as ranitidine and proton 
pump inhibitors, for example omeprazole have been shown to be efficacious in reducing 
gastric acid secretions and increasing gastric pH.  Omeprazole administered at a daily dose 
of 0.7 mg/kg to preterm infants with suspected GORD reduced acid GOR frequency and the 
overall degree of esophageal acid exposure (18).  In a double-blind placebo-controlled trial 
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of infants aged 3 to 12 months with GOR and/or oesophagitis, omeprazole compared to 
placebo significantly reduces oesophageal acid exposure, but not irritability (19). In contrast, 
Omari et al (20) demonstrated esomoprazole resulted in a significant decrease in the 
number of acid bolus reflux episodes and GORD related symptoms (20).  Both proton pump 
inhibitors and histamine two (H2) receptor blockers, however, have been associated with 
increased rates of necrotising enterocolitis (NEC) and serious bacterial infections (21).  A 
systematic review, which included one case controlled and one prospective cohort study 
demonstrated a significant association between NEC and inhibitors of gastric acid 
production, as well as a higher incidence of infection (sepsis and pneumonia) (22).  In a 
subsequent review, which included two retrospective and one prospective study, none of 
which were randomised, a significant association between use of ranitidine and an increased 
incidence of NEC was reported (23).  Furthermore, 12 of 33 VLBW neonates who received 
H2 antagonists developed blood stream infections, compared to 30 of 343 who did not 
receive the antagonist (24). A possible explanation is that the reduced gastric acid 
production might result in enhanced bacterial survival and gut colonization, increasing the 
risk of NEC development.   
 
Dopamine receptor antagonists, such as the macrolides domperidone and erythromycin, 
have been reported to improve clinical symptoms, pH study indices and histological changes 
on oesophageal biopsy in older children with GORD compared to placebo.  A systematic 
review evaluating the use of domperidone in the treatment of GORD in infants (25), 
however, concluded that there was insufficient evidence to support their use. Domperidone 
can precipitate cardiac arrhythmias (26), yet this survey showed it was currently used in 22% 
of UK neonatal units. Erythromycin use has been associated with hypertrophic pyloric 




Thickening agents were currently used in 27% of units.  A new preterm formula thickened 
with amylopectin used in 28 symptomatic preterm newborns was shown to reduce the 
number of acid GOR episodes detected by pH monitoring, but not non acid GORs as 
detected by MII monitoring (28).  Similarly, a study of 24 prematurely born infants 
demonstrated thickening a formula with amylopectin did reduce acid GOR, but not non acid 
GOR indexes nor GOR related apnoeas (29). A survey of neonatal feeding therapists and 
providers demonstrated that the majority were using thickened feeds for dysphagia or 
GORD, but noted variability in prescriptions for thickening agents regarding consistencies, 
thickening agents and recipes (30).   
 
In conclusion, we have demonstrated there is wide variation regarding investigation and 
medication use in infants with suspected GORD in neonatal units in the UK.  As in 2004, this 
likely reflects the limited evidence base and highlights the need for appropriate studies to 
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Table 1 Investigation used to establish a GOR diagnosis by percentage of units 
 
Trial of therapy      58% 
pH study       24% 
GI contrast study      23% 
MMI/pH study       6% 
Abdominal ultrasound     3% 




Table 2 Treatment used by percentage of units 
 
Gaviscon       60% 
Ranitidine       53% 
Thickening agents      27% 
Proton pump inhibitors     23% 
Domperidone       22% 
Erythromycin       6%   
 
 
 
